Cancer Genetics (CGIX) Reports Q3 EPS of $0.98 (Earlier)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Cancer Genetics Reports Third Quarter 2019 Financial Results and Provides Strategic Business Update
November 20, 2019 8:00 AM ESTRUTHERFORD, N.J., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the third quarter ended September 30, 2019.
RECENT STRATEGIC AND OPERATIONAL HIGHLIGHTS
Delivered on cost reduction initiatives and consolidated operational focus on drug discovery and preclinical servicesIncreased Discovery Services revenue in Q3 2019 to $2.1 million, an increase of $0.5 million, or 35% growth in Q3 2019 sequentially over Q2 2019Gross margin on Discovery Services was 53.2%,... More